Goldman Sachs
MXCT icon

Goldman Sachs’s MaxCyte MXCT Stock Holding History

Goldman Sachs’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
1,241,943
+82,924
+7% +$82.6K ﹤0.01% 4885
2026
Q1 		$814K Buy
1,159,019
+685,728
+145% +$640K ﹤0.01% 5243
2025
Q4 		$734K Buy
473,291
+53,768
+13% +$85.9K ﹤0.01% 5355
2025
Q3 		$663K Sell
419,523
-23,056
-5% -$40.1K ﹤0.01% 5329
2025
Q2 		$965K Buy
442,579
+155,751
+54% +$377K ﹤0.01% 4736
2025
Q1 		$783K Sell
286,828
-232,210
-45% -$916K ﹤0.01% 4879
2024
Q4 		$2.16M Buy
519,038
+13,650
+3% +$51.6K ﹤0.01% 4207
2024
Q3 		$1.97M Buy
505,388
+157,535
+45% +$664K ﹤0.01% 4174
2024
Q2 		$1.36M Buy
347,853
+162,994
+88% +$701K ﹤0.01% 4237
2024
Q1 		$775K Sell
184,859
-12,569
-6% -$59K ﹤0.01% 4504
2023
Q4 		$928K Buy
197,428
+14,392
+8% +$56K ﹤0.01% 4425
2023
Q3 		$571K Buy
183,036
+17,669
+11% +$71K ﹤0.01% 4598
2023
Q2 		$759K Buy
165,367
+30,147
+22% +$139K ﹤0.01% 4514
2023
Q1 		$669K Buy
135,220
+12,280
+10% +$60.5K ﹤0.01% 4659
2022
Q4 		$671K Sell
122,940
-335,480
-73% -$2.06M ﹤0.01% 4683
2022
Q3 		$2.98M Sell
458,420
-833,822
-65% -$4.65M ﹤0.01% 3606
2022
Q2 		$6.11M Buy
1,292,242
+288,504
+29% +$1.42M ﹤0.01% 2949
2022
Q1 		$7.02M Buy
1,003,738
+763,344
+318% +$5.21M ﹤0.01% 3028
2021
Q4 		$2.45M Buy
240,394
+84,011
+54% +$902K ﹤0.01% 4084
2021
Q3 		$1.91M Buy
+156,383
New +$2.36M ﹤0.01% 4245

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Goldman Sachs's MXCT Position: Q2 2026 in Review

Goldman Sachs increased its MaxCyte (MXCT) stake by 7.2% in Q2 2026, buying an estimated $82.6K and bringing the position to 1,241,943 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #4885.

Goldman Sachs first reported a position in MXCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $7.02M in Q1 2022. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Goldman Sachs held 1,241,943 shares of MaxCyte worth $1.53M as of Q2 2026.
  • Goldman Sachs bought 82,924 MaxCyte shares in Q2 2026, an estimated $82.6K.
  • MaxCyte made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4885 holding.
  • Goldman Sachs first reported a position in MaxCyte in Q3 2021 and has held it in 20 quarters since.
  • Goldman Sachs's MaxCyte position peaked at $7.02M in Q1 2022.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.